THE TGA has released details of a new "provisional approval pathway" for prescription drugs, allowing six years of registration on the basis of preliminary clinical data where there is the potential for a substantial benefit to Australian patients.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Mar 18
